A fatal course of COVID-19 during the Omicron surge: can you estimate your patients’ SARS-CoV-2 immune status?
-
Published:2023-11-06
Issue:1
Volume:52
Page:271-273
-
ISSN:0300-8126
-
Container-title:Infection
-
language:en
-
Short-container-title:Infection
Author:
Mersch Martin, Schlabe Stefan, Breitschwerdt Sven, Laufenberg Judith, Emmert Dorian, Aldabbagh Souhaib, Boesecke Christoph, Monin Malte BenediktORCID
Abstract
AbstractWe present a case of an ultimately fatal course of COVID-19 (coronavirus disease-19) in an 81-year-old female patient during the Omicron surge. The patient did not represent the typical patient at risk for severe COVID-19 with significant causes of immunodeficiency. However, she had been skeptical about the vaccination for severe acute respiratory syndrome virus-2 (SARS-CoV-2) and had refused it. Moreover, there had been no previous COVID-19 episodes. Our case report illustrates that with regard to SARS-CoV-2, immunologically naive patients are still at risk for severe and/or even fatal courses of COVID-19. We call to implement both, recommendations for SARS-CoV-2 vaccinations as well as for antiviral treatment.
Funder
Universitätsklinikum Bonn
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference10 articles.
1. Mikulska M, Testi D, Russo C, Balletto E, Sepulcri C, Bussini L, Dentone C, Magne F, Policarpo S, Campoli C, Miselli F, Cilli A, Ghiggi C, Aquino S, Di Grazia C, Giannella M, Giacobbe DR, Vena A, Raiola AM, Bonifazi F, Zinzani P, Cavo M, Lemoli R, Angelucci E, Viale P, Bassetti M, Bartoletti M. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders. Br J Haematol. 2023;201:628–39. https://doi.org/10.1111/bjh.18690. 2. Hübner YR, Spuck N, Berger M, Schlabe S, Rieke GJ, Breitschwerdt S, van Bremen K, Strassburg CP, Gonzalez-Carmona MA, Wasmuth JC, Rockstroh JK, Boesecke C, Monin MB. Antiviral treatment of COVID-19: which role can clinical parameters play in therapy evaluation? Infection. 2023. https://doi.org/10.1007/s15010-023-02081-0. 3. https://github.com/robert-koch-institut/COVID-19-Impfungen_in_Deutschland/blob/main/Deutschland_Impfquoten_COVID-19.csv (Access: Sep13, 2023) 4. Robert Koch-Institut. Monitoring des COVID-19-Impfgeschehens in Deutschland. Monatsbericht vom 04.05.2023. Online verfügbar unter: www.rki.de/covid-19-impfbericht. 5. Ishikawa K, Nascimento MC, Asano M, Hirata H, Itoh Y, Kelly EJ, Matsui A, Olsson U, Shoemaker K, Green J. One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): final analysis of a randomized, placebo-controlled phase ½ trial in Japan. Vaccine. 2023;41:4199–205. https://doi.org/10.1016/j.vaccine.2023.05.015.
|
|